

Invasive Pilzinfektionen auf der Intensivstation

Markus Ruhnke, Simone Rosseau und Barbara Graf, Berlin

Literatur

- Fridkin SK, Jarvis WR. Epidemiology of nosocomial fungal infections. *Clin Microbiol Rev* 1996;9:499-511.
- Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. *N Engl J Med* 2003;348:1546-??.
- McNeil MM, Nash SL, Hajjeh RA, Phelan MA, et al. Trends in mortality due to invasive mycotic diseases in the United States, 1980-1997. *Clin Infect Dis* 2001;33:641-7.
- Pappas PG, Rex JH, Sobel JD, Filler SG, et al. Guidelines for treatment of candidiasis. *Clin Infect Dis* 2004;38:161-89.
- Jarvis WR, Martone WJ. Predominant pathogens in hospital infections. *J Antimicrob Chemother* 1992;29(Suppl. A):19-24.
- Pfaller MA, Diekema DJ, Jones RN, Sader HS, et al. International surveillance of bloodstream infections due to *Candida* species: frequency of occurrence and in vitro susceptibilities to fluconazole, ravuconazole, and voriconazole of isolates collected from 1997 through 1999 in the SENTRY antimicrobial surveillance program. *J Clin Microbiol* 2001;39:3254-9.
- Pittet D, Li N, Woolson RF, Wenzel RP. Microbiological factors influencing the outcome of nosocomial bloodstream infections: a 6-year validated, population-based model. *Clin Infect Dis* 1997;24:1068-78.
- Beck-Sague C, Jarvis WR. Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. National nosocomial infections surveillance system. *J Infect Dis* 1993;167:1247-51.
- Trick WE, Fridkin SK, Edwards JR, Hajjeh RA, et al. Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989-1999. *Clin Infect Dis* 2002;35:627-30.
- Raad I, Hanna H, Boktour M, Girgawy E, et al. Management of central venous catheters in patients with cancer and candidemia. *Clin Infect Dis* 2004;38:1119-27.
- Vincent JL, Bihari DJ, Suter PM, Bruining HA, et al. The prevalence of nosocomial infection in intensive care units in Europe. Results of the European prevalence of infection in intensive care (EPIC) study. EPIC international advisory committee. *Jama* 1995;274:639-44.
- Tortorano AM, Peman J, Bernhardt H, Klingspor L, et al. Epidemiology of candidemia in Europe: results of 28-month European confederation of medical mycology (ECMM) hospital-based surveillance study. *Eur J Clin Microbiol Infect Dis* 2004;23:317-22.
- Geerdes HF, Ziegler D, Lode H, Hund M, et al. Septicemia in 980 patients at a university hospital in Berlin: prospective studies during 4 selected years between 1979 and 1989. *Clin Infect Dis* 1992;6:991-1002.
- Ruden H, Gastmeier P, Daschner FD, Schumacher M. Nosocomial and community-acquired infections in Germany. Summary of the results of the first national prevalence study (NIDEP). *Infection* 1997;4:199-202.
- Gastmeier P, Geffers C, Sohr D, Dettenkoffer M, et al. Five years working with the German nosocomial infection surveillance system (Krankenhaus Infektions Surveillance System). *Am J Infect Control* 2003;5:316-21. (Bitte den Titel nochmals überprüfen!!)
- Nguyen MH, Peacock JE Jr, Morris AJ, Tanner DC, et al. The changing face of candidemia: emergence of non-*Candida albicans* species and antifungal resistance. *Am J Med* 1996;100:617-23.
- Pfaller MA, Messer SA, Hollis RJ, Jones RN, et al. Trends in species distribution and susceptibility to fluconazole among blood stream isolates of *Candida* species in the United States. *Diagn Microbiol Infect Dis* 1999;33:217-22.
- Pfaller MA, Diekema DJ, International Fungal Surveillance Participant Group. Twelve years of fluconazole in clinical practice: global trends in species distribution and fluconazole susceptibility of bloodstream isolates of *Candida*. *Clin Microbiol Infect* 2004;10(Suppl. 1):11-23.
- Abi-Said D, Anaissie E, Uzun O, Raad I, et al. The epidemiology of hematogenous candidiasis caused by different *Candida* species. *Clin Infect Dis* 1997;24:1122-8.
- Pfaller MA, Jones RN, Messer SA, Edmond WB, et al. National surveillance of nosocomial blood stream infection due to species of *Candida* other than *Candida albicans*: frequency of occurrence and antifungal susceptibility in the SCOPE program. SCOPE participant group. Surveillance and control of pathogens of epidemiologic ??? (Titel unvollständig!!) *Diagn Microbiol Infect Dis* 1998;30:121-9.
- Marchetti O, Bille J, Eggiman P, Ruef C, et al. Epidemiology of candidemia in Swiss tertiary care hospitals: secular trends, 1991-2000. *Clin Infect Dis* 2004;38:311-20.
- Viscoli C, Girmenia C, Marinus A, Collette L, et al. Candidemia in cancer patients: a prospective, multicenter surveillance study by the invasive fungal infection group (IFIG) of the European organization for research and treatment of cancer (EORTC). *Clin Infect Dis* 1999;28:1071-9.
- Rangel-Frausto MS, Wiblin T, Blumberg HM, Saiman L, et al. National epidemiology of mycoses survey (NEMIS): variations in rates of bloodstream infections due to *Candida* species in seven surgical intensive care units and six neonatal intensive care units. *Clin Infect Dis* 1999;29:253-8.
- Kontoyiannis DP, Bodey GP. Invasive aspergillosis in 2002: an update. *Eur J Clin Microbiol Infect Dis* 2002;21:161-72.
- Strausbaugh LJ, Sewell DL, Ward TT, Pfaller MA, et al. High frequency of yeast carriage on hands of hospital personnel. *J Clin Microbiol* 1994;32:2299-300.
- Marr KA, Patterson T, Denning D. Aspergillosis. Pathogenesis, clinical manifestations, and therapy. *Infect Dis Clin North Am* 2002;16:875-94.
- Wey SB, Mori M, Pfaller MA, Woolson RF, et al. Risk factors for hospital-acquired candidemia. A matched case-control study. *Arch Intern Med* 1989;149:2349-53.
- Munoz P, Burillo A, Bouza E. Criteria used when initiating antifungal therapy against *Candida* spp. in the intensive care unit. *Int J Antimicrob Agents* 2000;15:83-90.
- Blumberg HM, Jarvis WR, Soucie JM, Edwards JE, et al. Risk factors for candidal bloodstream infections in surgical intensive care unit patients: the NEMIS prospective multicenter study. The national epidemiology of mycosis survey. *Clin Infect Dis* 2001;33:177-86.
- Kuhn DM, George T, Chandra J, Mukherjee PK, et al. Antifungal susceptibility of *Candida* biofilms: unique efficacy of amphotericin B lipid formulations and echinocandins. *Antimicrob Agents Chemother* 2002;46:1773-80.
- Anaissie EJ, Rex JH, Uzun O, Vartivarian S. Predictors of adverse outcome in cancer patients with candidemia. *Am J Med* 1998;104:238-45.
- Wenzel RP. Nosocomial candidemia: risk factors and attributable mortality. *Clin Infect Dis* 1995;20:1531-4.
- Wey SB, Mori M, Pfaller MA, Woolson RF, et al. Hospital-acquired candidemia. The attributable mortality and excess length of stay. *Arch Intern Med* 1988;148:2642-5.
- Nolla-Salas J, Sitges-Serra A, Leon-Gil C, Martinez-Gonzalez J, et al. Candidemia in non-neutropenic critically ill patients: analysis of prognostic factors and assessment of systemic antifungal therapy. Study group of

- fungal infection in the ICU. *Intensive Care Med* 1997;23:23-30.
35. Fraser VJ, Jones M, Dunkel J, Storfer S, et al. Candidemia in a tertiary care hospital: epidemiology, risk factors, and predictors of mortality [see comments]. *Clin Infect Dis* 1992;15:414-21.
 36. Gudlaugsson O, Gillespie S, Lee K, Vande Berg J, et al. Attributable mortality of nosocomial candidemia, revisited. *Clin Infect Dis* 2003;37:1172-7.
 37. Blot SI, Vandewoude KH, Hoste EA, Colardyn FA. Effects of nosocomial candidemia on outcomes of critically ill patients. *Am J Med* 2002;113:480-5.
 38. Michalopoulos AS, Geroulanos S, Mentzelopoulos SD. Determinants of candidemia and candidemia-related death in cardiothoracic ICU patients. *Chest* 2003;124:2244-55.
 39. Rex JH, Bennett JE, Sugar AM, Pappas PG, et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia study group and the national institute of allergy and infectious diseases. *N Engl J Med* 1994;331:1325-30.
 40. Rex JH, Pappas PG, Karchmer AW, Sobel J, et al. A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in non-neutropenic subjects. *Clin Infect Dis* 2003;36:1221-8.
 41. Mora-Duarte J, Betts R, Rotstein C, Lopes-Colombo A, et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. *New Engl J Med* 2002;347:2020-9.
 42. Ascoglu S, Rex JH, De-Pauw B, Bennett JE, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. *Clin Infect Dis* 2002;34:7-14.
 43. Jones JM. Laboratory diagnosis of invasive candidiasis. *Clin Microbiol Rev* 1990;3:32-45.
 44. Petri MG, König J, Moecke HP, Gramm HJ, et al. Epidemiology of invasive mycosis in ICU patients: a prospective multicenter study in 435 non-neutropenic patients. *Intensive Care Med* 1997;23:317-25.
 45. Sendid B, Caillot D, Baccouch-Humbert B, Klingspor L, et al. Contribution of the platelia candida-specific antibody and antigen tests to early diagnosis of systemic *Candida tropicalis* infection in neutropenic adults. *J Clin Microbiol* 2003;41:4551-8.
 46. Perfect JR, Comal GM, Lee JY, Kauffman CA, et al. The impact of culture isolation of *Aspergillus* species: a hospital-based survey of aspergillosis. *Clin Infect Dis* 2001;33:1824-33.
 47. Maertens J, Verhaegen J, Lagrou K, VanEldere J, et al. Screening for circulating galactomannan as a noninvasive diagnostic tool for invasive aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients: a prospective validation. *Blood* 2001;97:1604-10.
 48. Herbrecht R, Letscher-Bru V, Oprea C, Lioure B, et al. *Aspergillus* galactomannan detection in the diagnosis of invasive aspergillosis in cancer patients. *J Clin Oncol* 2002;20:1898-906.
 49. Viscoli C, Machetti M, Cappelano P, Bucchi P, et al. False-positive galactomannan platelia *Aspergillus* test results for patients receiving piperacillin-tazobactam. *Clin Infect Dis* 2004;38:913-6.
 50. Krcmery V Jr, Fuchsberger P, Trupl J, Blahova M, et al. Fungal pathogens in etiology of septic shock in neutropenic patients with cancer (short communication). *Int J Med Microbiol Virol Parasitol Infect Dis* 1993;278:562-5.
 51. Pittet D, Monod M, Suter PM, Frenk E, et al. *Candida* colonization and subsequent infections in critically ill surgical patients. *Ann Surg* 1994;220:751-8.
 52. Pfaller M, Cabezudo I, Koontz F, Bale M, et al. Predictive value of surveillance cultures for systemic infection due to *Candida* species. *Eur J Clin Microbiol* 1987;6:628-33.
 53. Kullberg BJ, Pappas P, Ruhnke M, Viscoli C, et al. Voriconazole compared with a strategy of amphotericin B followed by fluconazole of candidaemia in non-neutropenic patients. 14th ECCMID, Prague, May 1-4, 2004:abstract O245.
 54. Tuil O, Cohen Y. An open comparative multicenter study of intravenous (IV) itraconazole versus iv fluconazole in the treatment of candidemia in non-neutropenic patients. *Crit Care* 2003;7(Suppl. 2):63-4.
 55. Juster-Teicher A, Flidel-Rimon O, Amitay M, Even-Tov S, et al. High-dose liposomal amphotericin B in the therapy of systemic candidiasis in neonates. *Eur J Clin Microbiol Infect Dis* 2003;22:603-7. Epub 2003 Sep 12 (Bitte Literaturangaben nochmal überprüfen!!)
 56. Ostrosky-Zeichner L, Marr KA, Rex JH, Cohen SH. Amphotericin B: Time for a new gold standard. *Clin Infect Dis* 2003;37:415-25.
 57. Abele-Horn M, Kopp A, Sternberg U, Ohly A, et al. A randomized study comparing fluconazole with amphotericin B/5-flucytosine for the treatment of systemic *Candida* infections in intensive care patients. *Infection* 1996;24:426-32.
 58. Saag MS, Graybill RJ, Larsen RA, Pappas PG, et al. Practice guidelines for the management of cryptococcal disease [In process citation]. *Clin Infect Dis* 2000;30:710-8.
 59. Francis P, Walsh TJ. Evolving role of flucytosine in immunocompromised patients: new insights into safety, pharmacokinetics, and antifungal therapy. *Clin Infect Dis* 1992;15:1003-18.
 60. Denning DW. Therapeutic outcome in invasive aspergillosis. *Clin Infect Dis* 1996;23:608-15.
 61. Wingard JR, Kubilis P, Lee L, Yee G, et al. Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis. *Clin Infect Dis* 1999;29:1402-7.
 62. Denning DW, Ribaud P, Milpied N, Caillot D, et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. *Clin Infect Dis* 2002;34:563-71.
 63. Herbrecht R, Denning DW, Patterson TF, Bennett JE, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. *N Engl J Med* 2002;347:408-15.
 64. Böhme A, Ruhnke M, Buchheidt D, Karthaus M, et al. Treatment of fungal infections in hematology and oncology - guidelines of the infectious diseases working party (AGIHO) of the German society of hematology and oncology (DGHO). *Ann Hematol* 2003;82(Suppl. 2):S133-40.
 65. Ellis M, Spence D, De-Pauw B, Meunier F, et al. An EORTC international multicenter randomized trial (EORTC number 19923) comparing two dosages of liposomal amphotericin B for treatment of invasive aspergillosis. *Clin Infect Dis* 1998;27:1406-12.
 66. Caillot D, Bassaris H, McGeer A, Arthur C, et al. Intravenous itraconazole followed by oral itraconazole in the treatment of invasive pulmonary aspergillosis in patients with hematologic malignancies, chronic granulomatous disease, or AIDS. *Clin Infect Dis* 2001;33:e83-90.
 67. Steinbach WJ, Stevens DA, Denning DW. Combination and sequential antifungal therapy for invasive aspergillosis: review of published in vitro and in vivo interactions and 6 281 clinical cases from 1966 to 2001. *Clin Infect Dis* 2003;37(Suppl. 3):S188-224.
 68. Eggimann P, Francioli P, Bille J, Schneider R, et al. Fluconazole prophylaxis prevents intra-abdominal candidiasis in high-risk surgical patients. *Crit Care Med* 1999;27:1066-72.
 69. Pelz RK, Hendrimal CW, Swoboda SM, Diener-West M, et al. Double-blind placebo-controlled trial of fluconazole to prevent candidal infections in critically ill surgical patients. *Ann Surg* 2001;233:542-8.
 70. Garbino J, Lew DP, Romand JA, Hugonnet S, et al. Prevention of severe *Candida* infections in non-neutropenic, high-risk, critically ill patients: a randomized, double-blind, placebo-controlled trial in patients treated by selective digestive decontamination. *Intensive Care Med* 2002;28:1708-17.
 71. Groll AH, Piscitelli CW, Walsh TJ. Clinical pharmacology of systemic antifungal agents: a comprehensive review of agents in clinical use, current investigational compounds, and putative targets for antifungal drug development. *Adv Pharmacol* 1998;44:343-501.
 72. Eggimann P, Garbino J, Pittet D. Management of *Candida* species infections in critically ill patients. *Lancet Infect Dis* 2003;3:772-85.
 73. Just-Nübling G. Therapy of candidiasis and cryptococcosis in AIDS. *Mycoses* 1994;37(Suppl. 2):56-63.
 74. Brouwer AE, Rajanuwong A, Chierakul W, Griffin GE, et al. Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial. *Lancet* 2004;363:1764-7.